HeartSciences enters the fiscal year as a pre-revenue AI-ECG developer and exits it, on paper, as the founding public vehicle for a Digital Currency Group Zcash mining platform, an all-stock merger announced in late June 2026 that hands control to Fortitude Mining Holdings and rebrands the combined listing under the ticker TUDE. The deal functions as a reverse takeover: Fortitude merges beneath HeartSciences' listed shell, Fortitude's parent DCG carries roughly 95 percent of the combined entity on a fully diluted basis, and HeartSciences holders retain a minority float whose per-share value hangs on an exchange ratio tied to the pre-closing share count and share price. The investment case is therefore no longer a medical case, and no amount of diligence on MyoVista changes that arithmetic. The thesis lives and dies on Zcash economics, deal completion, and minority-shareholder treatment, three forces the legacy tools for valuing device companies never touch. Reading the name correctly starts by admitting the chassis was the product.
The single most important recent development is the late-June merger agreement and the sequence that followed it: a Nasdaq equity-deficiency letter, a private placement sold to Fortitude at a volume-weighted price near the listing's summer midpoint, and definitive proxy material reaching EDGAR within a fortnight of year-end reporting. Each step tightens the coupling between the medical shell and the buyer, and each substitutes Fortitude's balance sheet and goodwill for HeartSciences' own absent capital. The mechanism matters because HeartSciences closed the July quarter with a working capital deficit, a stockholders' deficit, and cash measured in the tens of thousands, so the merger functions as the only solvent exit the company has engineered from going-concern territory.
The core tension is the asymmetry baked into the structure. HeartSciences shareholders are being asked to swap control of their listing for a small, undiluted slice of a crypto-mining business whose coin exposure, ZEC, trades at violent multiples of its levels from a year earlier, and whose operating costs remain undisclosed to them. Zcash's trailing move made this deal attractive on paper, and the same volatility that opened the valuation gap also makes the combined entity's reported economics hostage to a single token price. A privacy-token tape that moves by double-digit daily percentages can turn the buyer's goodwill from a tailwind into a trap between consecutive proxy amendments. The medical business never faced a pricing input anywhere near that violent, which is why risk here concentrates faster than it did even during the shell's worst capital raises.
The catalyst calendar is short. The shareholder vote under the definitive proxy lands against a September 18, 2026 Nasdaq plan deadline, meaning the listing-defense clock and the merger clock converge inside the same fortnight as the fiscal year's second quarter gets reported. Traders holding the name through that window are implicitly underwriting deal completion, ZEC staying bid, and Nasdaq tolerance for the float shrink, all at once.
HeartSciences spent the pre-merger decade trying to convert a signal-processing idea into a cleared medical device. The MyoVista wavECG concept reads the distribution of energy across a cardiac cycle, consumes a standard twelve-lead recording, and layers continuous wavelet transform analytics plus learning models on top, with the stated aim of flagging cardiac dysfunction from beats that conventional interpretation scores as normal. Any of the several revenue paths behind that idea remained unbuilt at the start of the fiscal year: United States commercialization of the hardware stayed blocked behind a pending 510(k) submission lodged in December 2025, and the cloud platform called MyoVista Insights, designated a Medical Device Data System and exempt from that regulatory route, became the company's self-declared primary commercial focus in the July quarter filing.
The strategic pivot that defines the name, however, happened outside the medical segment entirely. On June 23, 2026, HeartSciences entered an Agreement and Plan of Merger with Fortitude Mining Holdings, a Delaware corporation wholly owned by Digital Currency Group, alongside Fortitude Mining HoldCo and a HeartSciences-owned merger sub named Cordis Acquisition. The transaction is structured as a reverse acquisition: the shell contributes substantially all assets and liabilities into a new subsidiary, Fortitude merges beneath the shell through Cordis, Fortitude becomes the operating business, and the combined company keeps the Nasdaq listing under a new ticker, TUDE, subject to market approval. Fortitude chief executive Andrea Childs runs the combination, while longtime HeartSciences chief executive Andrew Simpson continues to lead the retained healthcare unit.
Ownership math from the announcement frames who wins and loses at closing. DCG, as Fortitude's sole stockholder, holds roughly 95 percent of the combined company on a fully diluted basis, leaving HeartSciences' existing holders a roughly single-digit minority once the exchange ratio and a freshly created non-economic Class V voting stock are applied. Fortitude also contributes $2.0M in cash or Zcash coin for shares of the new Class A common stock, and all of the shell's Series C and Series D convertible preferred converts at the effective time. A cover page check on the definitive proxy assigns roughly 390K Class A shares to former HeartSciences holders against a fully diluted float near 9.8M, numbers that place the legacy equity's slice of the listed business near four percent.
Why the arrangement matters to the thesis is straightforward: the listed vehicle's economics stop being HeartSciences' and start being Fortitude's at the effective time. MyoVista passes into a healthcare unit inside a crypto-mining group, its capital competitors inside that group's budget, and its fate riders on a parent that prices it, publicly, as a side business. Every future claim on the combined company's cash flows gets paid after the mining economics clear, which is why the remainder of this report treats Zcash pricing, deal completion, and dilution mechanics as the thesis variables, with the medical residue valued essentially at carry value. The sequence of events that produced this structure is worth keeping visible, because it shows a seller-engineered exit inside a year of that going-concern language arriving. Deals of this shape reward holders only to the extent the incoming operator values float credibility, and the arrival order here, deal first, medical demotion second, proxy third, reads as coordination rather than drift.
The medical chassis of this deal is thin, but it deserves a precise description because it is what legacy holders actually contributed. MyoVista wavECG is a hardware and software device that acquires a conventional twelve-lead electrocardiogram and processes it through continuous wavelet transform signal analysis, mapping the energy of each beat into an array that learning models then score for cardiac dysfunction. The device was submitted to the Food and Drug Administration for 510(k) premarket clearance in December 2025, and the filing stayed under review through the July quarter, with the company stating plainly that clearance carries no assurance. Management paired that caution with a second, heavier admission: the commercial path additionally needs an impaired cardiac relaxation algorithm, referred to as the e-prime measurement, which requires further development and validation against revised age-based thresholds issued under updated American Society of Echocardiography guidelines, plus a separate regulatory submission of its own.
That e-prime dependency is the quiet structural fact in the medical story. Updated guidance for assessing left ventricular diastolic dysfunction reset the age-based thresholds that any screening algorithm has to match, so the algorithm as originally developed no longer lines up with the clinical standard its users practice. The consequence is a second validation cycle stacked behind the first, funded by a company with a stockholders' deficit, inside an industry where cloud-based and wearable cardiac screening entrants multiplied during the device's long development window. Even sympathy for the engineering is a thin reed here; the moat question in AI-assisted electrocardiography belongs to whoever owns distribution into clinics, and the device owns none of it at the moment of its own clearance attempt.
MyoVista Insights, the cloud platform, is the piece the company elected to prioritize. It is classified as a Medical Device Data System and is exempt from the 510(k) route, designed to organize electrocardiogram studies, streamline waveform reading workflows, and host AI-ECG algorithms from multiple vendors inside health systems. The exemption is a genuine regulatory convenience, since it removes the pre-market gate that blocks the hardware, and it explains why management redirected remaining resources toward the platform in the most recent quarter. The catch is commercial: the platform enters a crowded health-system software market with no disclosed paying customers, no disclosed pricing plan, and a sales force the listed entity has never assembled. Software distribution in cardiology is won through installed imaging and ECG management relationships, and the platform's multi-vendor hosting pitch, whatever its technical merit, competes against incumbents who bundle analysis into hardware the hospitals already own.
Call the moat what the filings call it, which is nothing yet. The technology's differentiation claims rest on signal-processing novelty that has never been tested against a cleared competitor, a cleared predicate, or a paying buyer at commercial scale, and every month the review extends the predicate gap widens rather than narrows. What HeartSciences actually contributed to the merger is a Nasdaq registration, a decade of regulatory positioning, a stalled device story, and an intangible-assets balance of about $1.7M against accumulated losses near $88M. In the combined entity, that residue becomes a healthcare business unit with no disclosed revenue budget and no disclosed operator plan beyond a retained chief executive, which is the context any future MyoVista milestone needs to be read through.
The audited fiscal year that closed in late spring reads like a company that had stopped trying to be a company. Total revenue for the year came in at $4,319 against $4,350 the prior year, marking the fourth straight fiscal year with essentially no commercial sales, and the cost of providing that trivial service slightly outweighed it. The net loss ran to $9.1M, a touch worse than the $8.8M of the year before, with selling, general and administrative expense consuming the majority of the spend. Cash on the year-end balance sheet was $1.7M, and the year-over-year improvement came only because financing recovered more than operations consumed, a treadmill pattern that has defined this listing since its shell days.
Equity and debt lines explain why the Nasdaq letter arrived. Total stockholders' equity closed the year at $226,060, an order of magnitude below the listing standard the exchange applies, while the accumulated deficit passed the $85M mark. The working capital position simultaneously ran a $2.3M deficit. The capital structure stacks a Streeterville note with $3.6M original principal on top of an older stack of convertible instruments, and survival during the year depended on serial emergency fixes. Those fixes included debt-for-equity exchanges that retired note principal as common stock, preferred conversions, and a private placement from Fortitude priced at $2.43 per share. Each fix added shares. None added a revenue path, and the summer quarter's cash decline to a $29,906 closing balance shows the burn arriving faster than the fixes did.
The July quarter itself put the terminal arithmetic on the record. Quarterly revenue printed at $2,417, and the net loss ran $3.2M for the three-month period. The accumulated deficit passed the $88M mark alongside a stockholders' deficit of $2.0M. A working capital deficit of $4.8M sat on top of both, built on notes payable, accrued interest, and trade payables. Management combined two admissions in the same liquidity note: existing cash was judged insufficient to fund operations for the next twelve months, and resources were redirected principally toward the MyoVista Insights platform. Read together, the two statements demote the hardware commercialization plan that once justified the whole listing into a long-dated option inside a company that was, by its own filing, running out of solvent quarters.
What the numbers describe, mechanically, is a listing being cannibalized by its own survival costs. Common shares outstanding rose from 3.19M at year end to 3.90M by late July, with the dilution arriving through note conversions, accrued-interest stock, restricted management grants, and an August placement. The slice available to legacy holders shrinks again at closing through the exchange ratio, so each emergency issuance compounds at the worst possible moment, right before the denominator event that reprices the whole float. Share-count creep of this shape is not a financing footfault; it is the visible mechanism by which economic claims migrate from the public to the controlling party ahead of a control transaction. Every quarter of this pattern transfers more of the eventual combined float away from the people who held the listing at the start of the fiscal year, which is why a going-concern flag here is not a warning about a hospital group; it is the observable mechanism of control transfer.
The forward calendar compresses three clocks into one window, which is what makes the name trade like an event. The Nasdaq letter gave the company until September 18, 2026 to submit a compliance plan under the equity standard, and management's response rides on the merger closing rather than a capital raise, so the plan deadline and the deal calendar effectively share a due date. The definitive proxy filed in the second week of September schedules the shareholder push that approves the exchange ratio, the charter changes, and the new capital structure, and management publicly indexed the closing to the second half of the calendar year. A reverse takeover that converts a listed medical shell into a token-native mining platform is a heavier regulatory lift than a device opinion letter, and every one of those clocks can slip independently.
The events ledger since the June announcement shows a buyer engineering margin into its entry, one instrument at a time. In mid-August, Fortitude bought 411,522 newly issued shell shares at $2.43, the volume-weighted anchor price, leaving the seller's stake growing in the very vehicle it already controls at closing. Weeks later, a subscription amendment converted part of that investment's status through warrant coverage, a seller asking for downside protection on a deal it unilaterally controls is a telling detail. Amendment No. 1 on July 27 reworked redemption mechanics in the new operating agreement and rewrote shareholder-action requirements in the post-closing charter, the quiet structural amendments that shift voting gravity toward the incoming controlling party.
One named event deserves its own paragraph because it is the clearest window into how control settles. In late August, the company disclosed that a large block transaction had passed through the listing, a counterparty sale large enough to register as a separate disclosure event, and the market read it as pre-positioning rather than accident, given that a minority float in a Zcash platform has strategic value to anyone consolidating into TUDE. The exact identities inside that block remain partially disclosed; what is precise is the direction of travel: voting power and economics both compressing toward the buyer while the public spectrum thins.
Execution risk, stated plainly, is that the entire value proposition sits on approvals while the liability side deteriorates. A vote that clears into an approving Nasdaq panel and a cooperative token tape produces the base-case listing sketched later in this report; three conditions resolving differently any week before closing reprice the certificate with no protection offered to the small holder. The proxy calendar leaves almost no slack between shareholder action and the exchange's plan deadline, so a single extension request converts the completion story into an emergency listing-defense story overnight. The going-concern language in the July filing says existing cash is insufficient for the next twelve months under current burn, which means every month of deal slippage deepens the hole Fortitude has to plug and weakens the leverage of the small float that is supposed to approve the deal. On the Fortitude side, its production scale, cost base, and hash allocation were never disclosed in filings HeartSciences holders can audit; all of the disclosed operating detail lives in buyer-side marketing materials, outside the audited perimeter. An approval gives holders shares in a business they cannot underwrite with the documents at hand; a rejection gives them a shell that no longer covers its own costs.
The counterargument deserves the first word: a sophisticated buyer paying with real securities, a cash contribution, and warrant coverage inside a surging coin complex can be read as validation rather than predation. Digital Currency Group is a fixture of the digital-asset institutional landscape, ZEC's price action gave combined-entity revenue real operating leverage, and a public listing with a seasoned miner behind it offers something the medical story never delivered, which is a solvent operator. On that reading, legacy holders who keep a few percent of a business the buyer plans to scale up participate in upside the shell could never manufacture alone, and the August stake build at volume-weighted prices demonstrates conviction in writing. The reply is that validation is observable in the direction of protection, not only in the direction of purchase: the buyer took warrants from the float it controls while the float's own cash ran to a few tens of thousands, and protection asymmetry of that shape has historically meant the negotiating table was tilted before the meeting started.
The dual-delisting scenario is the cleanest measure of standalone downside. A merger failure leaves the listing facing the equity standard it already failed, a Nasdaq plan deadline it has to satisfy within weeks, and a twelve-month funding gap that its own liquidity note describes as unbridgeable without new capital. Nasdaq cure paths in that scenario include another reverse split, a history this listing already carries from a prior hundred-to-one episode, and the recently amended listing rules. Those amendments mean a post-split failure starts delisting immediately rather than setting a fresh compliance clock. The terminal state of a failed deal is a medical shell with a stockholders' deficit, no commercial product, and a two-count listing problem, which is roughly the floor the merger is bid against.
Deal-completion risk has a second layer that pure binary math usually misses. Even a successful vote closes into a token whose trailing move made the entire transaction economically attractive, and a slide backward in ZEC between signing and closing reprices the securities that closing hands to legacy holders at the effective time. The combined entity's production cost base was never put through a public-audit lens, and therefore the float's slice of that business carries both coin volatility and information opacity at once. Hybrid exposures like this tend to trade on the token's every daily move while inheriting none of the disclosure protections that a mining comparably priced on exchange would carry.
Downside scenarios, ranked by observable probability, stack as follows. Collapse of the deal leaves the shell with a going-concern flag and a delisting clock, where recovery value approaches the residual intangible assets and the cash needed to survive the process comes from further seller-side or emergency financing at increasingly punitive terms. Completion into a falling ZEC tape leaves holders with a listing whose reported earnings swing on coin volatility, where the historical pattern of hash-price feedback loops has erased platform margins before. Completion without restoration of adequate disclosure leaves the minority stranded on information and scale, a passive stake near four percent of a controlled platform, with the Class V voting structure formalizing the control asymmetry they already priced into the agreement. Each of those scenarios has a distinct early-warning signature, which is the practical use of naming them. A failed vote shows up first as proxy-delay amendments and then as a liquidity crunch on the thinning float; a completed-into-weakness deal shows up as opening-quarter commentary from the new operator that leads with treasury holdings; disclosure starvation shows up as a first post-closing quarter with production headlines and no cost line.
The framework has to start from what the market is actually pricing, because no earnings multiple attaches to a shell posting quarterly revenue under a grand and carrying a terminal pre-FDA device story. At the final pre-publication close, the tape held a $3.73 print for the September session preceding the holiday weekend. Roughly 3.9M common shares outstanding, plus the converting Series D preferred stack, put the implied equity value above $16M. That is up from a band around $1.67 in late May, and the re-rate accelerated into the fortnight when ZEC pushed through its early-September level near $1,228. Paying up like that means the tape re-multiplies: the certificate now trades as a claim on post-closing TUDE rather than as a claim on the audited chassis, with the medical residue rounding toward zero.
Decomposing the current premium builds the base case. Disclosed production was annualized at 157,000 ZEC as of late May, and the early-September tape turns that into a gross run-rate production value above $150M per year. The tape near $1,100 per coin made the platform's anchoring economics visible for the first time in a public window, and the production sits inside a vehicle that also owns a utility-grade power portfolio. That production figure sits before electricity, hosting, operating expense, or pool fees, and layering on an unknown cost base is what stops the run-rate from being read as earnings. Public miner comparables price reported production at low single-digit multiples of gross coin revenue once costs are deducted, and layered on top, the contributing parent adds its own pre-equity claim value of the coin stack and power assets into the combined vehicle. The complication is that cost per coin was never disclosed, which means the float's four-percent slice cannot be audited against any stated margin, and the premium the market has already paid bundles completion probability, token momentum, and scarcity of float into a single price.
Bear, base, and bull frames quantify what those mechanics imply. The bear case prices completion failure against the standalone shell with a stockholders' deficit, residual intangibles near $1.7M, a Nasdaq delisting clock, and a going-concern flag, where terminal recovery sits in the high single-digit-percent of the current quote per share once the listing loses its Zcash relevance. The base case prices a completed deal with ZEC near the $1,000 to $1,300 band that held through early September; a four-percent claim on a platform running break-even-to-positive cash economics places the bulk of current value as defensible but brutal to downside moves, because a coincident token retracement plus closing slippage cuts the minority's slice value faster than the token's own percentage loss. The bull case prices ZEC holding triple figures with hash economics at scale plus power-asset accretion from the buyer's stated acquisitions, where the minority's residual claim, being levered to a fixed share count, outperforms on any ZEC upside as long as the buyer keeps funding expansion with its own dilution.
One named-variable map keeps the framework honest for monitoring. Three variables drive essentially all of the range: the exchange ratio and closing frequency, the ZEC price path around the $1,000 to $1,300 corridor that held through early September, and the fill rate of the float after closing, meaning how much of the roughly 390K legacy-share accounting remains tradable versus absorbed by strategic acquirers. Each variable can be repriced weekly from public tape, and each breaks the thesis in a different direction, which is why the report's judgment rests on monitoring all three instead of anchoring to any single scalar. The framework also implies a discipline the token tape punishes: nothing about the certificate's weekly correlation to ZEC is evidence about its return once closing mechanics are priced, because completion probability and coin momentum bundle into a single quote. Separating those two drivers is the only way a holder can tell whether the next leg of the tape is paying for the deal or for the coin.
The judgment this report lands on is that the float inherits an unhedged option on a controlled buyer's goodwill, and the option's value is real but structurally fragile. HeartSciences ceased to be a medical story in substance sometime during the year the audited filing closed, and the merger converts that reality into a legal fact at closing if the vote clears. A post-closing position is a passive minority in a platform whose owner gets to set cost of production, capital allocation, and eventually the float's own tradable supply, all while the anchor asset trades with the daily violence of a privacy-token market. Nothing in the disclosed deal terms gives the minority a protection against any of those levers beyond the token price itself, and the warrant coverage the buyer negotiated for itself confirms the negotiating posture. That posture is the lens through which every future governance proposal from the controlling party should be refracted. The lesson of the two-month negotiation record, placement first, protection second, capital-structure rewrite third, is that veto rights over the operating agreement are where the small float's remaining power actually lives.
The single most load-bearing risk to carry forward is the combination of an unaudited cost base and a captive float. If Fortitude's true cash margins on 157,000 annualized coins lean even moderately negative, the minority's slice is a claim on a treasury portfolio rather than on operating cash flow, and treasury claims in miner listings historically compress toward coin-value parity whenever power portfolios disappoint. The counterweight the buyer really supplies is not margin disclosure; it is its own balance sheet continuance, and the thesis variables named throughout, the exchange ratio, the ZEC corridor, and the float's post-closing fill, all monetize only if that sponsor keeps funding the platform through its own dilution.
Set against the standalone alternative, the merger remains the least bad outcome available to the shell. A rejected deal leaves a listing with a passed exchange standard, a twelve-month liquidity gap its own filing calls unbridgeable, no revenue engine, and a regulatory path stuck behind a second validation cycle in the device business. Completion hands legacy holders a sliver of real operating economics instead of a slow zero, and the market's implied cap near $16M says that sliver plus substantial completion probability is already the consensus anchor, with the September quote effectively paying Zcash-kind prices for a Zcash-kind business.
The monitoring plan fits on one hand. First, the vote margin and whether any registered 13D activity appears on the legacy shareholder rolls, which reconciles the four-percent claim against real consolidating demand. Second, the post-closing operating disclosure cadence, where a buyer that publishes cost per coin and power-asset accretion within its first two quarters is telling holders the platform values float credibility; a buyer that publishes only production headlines is managing for the other ninety-five percent. Third, the ZEC corridor itself, whose early-September climb toward $1,228 set the psychological ceiling that the deal announcement is now priced off. A position taken here is a bet on all three resolving in the same direction, and the honest label for that bet is concentrated crypto-index risk held through a single listed trustee whose incentives are referenceable but unproven. Published as judgment, the closing verdict reads: the merger offers the shell's holders the only solvent exit anyone has structured, pays them in a currency that moved against nobody in the trailing year, and asks them to accept control, disclosure, and supply risk in exchange, a trade whose expected value depends far more on a buyer's future conduct than on anything the medical chassis ever promised.